Triglyceride-glucose index improves risk prediction beyond traditional risk factors and hypertension mediated organ damage in healthy adults.

Autor: Blicher MK; Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark; Department of Endocrinology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: marie.blicher@rsyd.dk., Frary C; Cardiology Section of the Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark., Pareek M; Center for Translational Cardiology and Pragmatic Randomized Trials, Copenhagen University Hospital - Herlev and Gentofte, Denmark., Stidsen JV; Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark., Vishram-Nielsen JKK; Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark, Copenhagen, Denmark., Rasmussen S; Department of Clinical Physiology and Nuclear Medicine, Gentofte Hospital, Gentofte, Denmark., Bonnema SJ; Department of Endocrinology, Odense University Hospital, Odense, Denmark., Højlund K; Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark., Olsen MH; Cardiology Section of the Department of Internal Medicine, Holbaek Hospital, Holbaek, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Olesen TB; Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark; Department of Internal Medicine, Kolding Hospital, Kolding, Denmark.
Jazyk: angličtina
Zdroj: Nutrition, metabolism, and cardiovascular diseases : NMCD [Nutr Metab Cardiovasc Dis] 2024 Nov; Vol. 34 (11), pp. 2446-2454. Date of Electronic Publication: 2024 Jun 20.
DOI: 10.1016/j.numecd.2024.06.010
Abstrakt: Background and Aims: Triglyceride-glucose (TyG) index, a surrogate measure of insulin resistance, is associated with hypertension mediated organ damage (HMOD) and cardiovascular disease. This study investigated the association between TyG index and major adverse cardiovascular events (MACE) and its interaction with traditional risk factors and HMOD.
Methods and Results: Healthy subjects recruited from the general population were thoroughly examined and followed for MACE using nation-wide registries. Cox proportional hazard models were used to calculate the association between TyG index and MACE occurrence. Models were adjusted for Systematic Coronary Risk Evaluation (SCORE) risk factors, pulse wave velocity, left ventricular mass index, carotid atherosclerotic plaque status, and microalbuminuria. Continuous net reclassification and Harrell's Concordance index (C-index) were used to assess the added prognostic value of TyG index. During a follow-up period of mean 15.4 ± 4.7 years, MACE were observed in 332 (17%) of 1970 included participants. TyG index was associated with MACE; HR = 1.44 [95%CI:1.30-1.59] per standard deviation. After adjustment for traditional cardiovascular (CV) risk factors, HR was 1.16 [95%CI:1.03-1.31]. The association between TyG index and MACE remained significant after further adjustment for each HMOD component. However, this finding was evident only in subjects aged 41 or 51 years (HR = 1.39; 95%CI:1.15-1.69). Including TyG index in a risk model based on traditional CV risk factors improved C-index with 0.005 (P = 0.042).
Conclusion: In this population-based study of healthy middle-aged subjects, TyG index was associated with MACE independently of traditional CV risk factors and HMOD. TyG index may have a potential role in future risk prediction systems.
Competing Interests: Declaration of competing interest The authors received no financial support for the research, authorship, and / or publication of this article. Dr. Manan Pareek discloses the following relationships – Advisory Board: AstraZeneca, Janssen-Cilag, Novo Nordisk; Grant Support: Danish Cardiovascular Academy funded by the Novo Nordisk Foundation and the Danish Heart Foundation (grant number: CPD5Y-2022004-HF); Speaker Honorarium: AstraZeneca, Bayer, Boehringer Ingelheim, Janssen-Cilag. Prof. Michael Hecht Olsen discloses that he has received speaker fees from Novo Nordisk Foundation, Boehringer & Ingelheim, Astra Zeneca and Teva. The remaining authors have no disclosures to report.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: